A Pipeline for the Automatic Identification of Randomized Controlled Oncology Trials and Assignment of Tumor Entities Using Natural Language Processing.

IF 2.5 3区 医学 Q3 ONCOLOGY
Oncology Pub Date : 2025-06-13 DOI:10.1159/000546970
Paul Windisch, Fabio Dennstädt, Carole Koechli, Robert Förster, Christina Schröder, Daniel M Aebersold, Daniel R Zwahlen
{"title":"A Pipeline for the Automatic Identification of Randomized Controlled Oncology Trials and Assignment of Tumor Entities Using Natural Language Processing.","authors":"Paul Windisch, Fabio Dennstädt, Carole Koechli, Robert Förster, Christina Schröder, Daniel M Aebersold, Daniel R Zwahlen","doi":"10.1159/000546970","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most tools trying to automatically extract information from medical publications are domain agnostic and process publications from any field. However, only retrieving trials from dedicated fields could have advantages for further processing of the data.</p><p><strong>Methods: </strong>We trained a small transformer model to classify trials into randomized controlled trials (RCTs) vs. non-RCTs and oncology publications vs. non-oncology publications. In addition, we used two large language models (GPT-4o and GPT-4o mini) for the same task. We assessed the performance of the three models and then developed a simple set of rules to extract the tumor entity from the retrieved oncology RCTs.</p><p><strong>Results: </strong>On the unseen test set consisting of 100 publications, the small transformer achieved an F1-score of 0.96 (95% CI: 0.92 - 1.00) with a precision of 1.00 and a recall of 0.92 for predicting whether a publication was an RCT. For predicting whether a publication covered an oncology topic, the F1-score was 0.84 (0.77 - 0.91) with a precision of 0.75 and a recall of 0.95. GPT-4o achieved an F1-score of 0.94 (95% CI: 0.90 - 0.99) with a precision of 0.89 and a recall of 1.00 for predicting whether a publication was an RCT. For predicting whether a publication covered an oncology topic the F1-score was 0.91 (0.85 - 0.97) with a precision of 0.91 and a recall of 0.91. The rule-based system was able to correctly assign every oncology RCT in the test set to a tumor entity.</p><p><strong>Conclusion: </strong>In conclusion, classifying publications depending on whether they were randomized controlled oncology trials or not was feasible and enabled further processing using more specialized tools such as rule-based systems and potentially dedicated machine learning models.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-16"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546970","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Most tools trying to automatically extract information from medical publications are domain agnostic and process publications from any field. However, only retrieving trials from dedicated fields could have advantages for further processing of the data.

Methods: We trained a small transformer model to classify trials into randomized controlled trials (RCTs) vs. non-RCTs and oncology publications vs. non-oncology publications. In addition, we used two large language models (GPT-4o and GPT-4o mini) for the same task. We assessed the performance of the three models and then developed a simple set of rules to extract the tumor entity from the retrieved oncology RCTs.

Results: On the unseen test set consisting of 100 publications, the small transformer achieved an F1-score of 0.96 (95% CI: 0.92 - 1.00) with a precision of 1.00 and a recall of 0.92 for predicting whether a publication was an RCT. For predicting whether a publication covered an oncology topic, the F1-score was 0.84 (0.77 - 0.91) with a precision of 0.75 and a recall of 0.95. GPT-4o achieved an F1-score of 0.94 (95% CI: 0.90 - 0.99) with a precision of 0.89 and a recall of 1.00 for predicting whether a publication was an RCT. For predicting whether a publication covered an oncology topic the F1-score was 0.91 (0.85 - 0.97) with a precision of 0.91 and a recall of 0.91. The rule-based system was able to correctly assign every oncology RCT in the test set to a tumor entity.

Conclusion: In conclusion, classifying publications depending on whether they were randomized controlled oncology trials or not was feasible and enabled further processing using more specialized tools such as rule-based systems and potentially dedicated machine learning models.

基于自然语言处理的随机对照肿瘤试验自动识别和肿瘤实体分配管道。
背景:大多数试图从医学出版物中自动提取信息的工具都是领域无关的,并且可以处理来自任何领域的出版物。但是,仅从专用字段检索试验可能对数据的进一步处理有好处。方法:我们训练了一个小型变压器模型,将试验分为随机对照试验(rct)与非rct,肿瘤学出版物与非肿瘤学出版物。此外,我们使用了两个大型语言模型(gpt - 40和gpt - 40 mini)来完成相同的任务。我们评估了这三种模型的性能,然后开发了一套简单的规则,从检索到的肿瘤学随机对照试验中提取肿瘤实体。结果:在由100篇出版物组成的未见过的测试集上,小型变压器在预测出版物是否为RCT方面达到了f1得分0.96 (95% CI: 0.92 - 1.00),精度为1.00,召回率为0.92。对于预测出版物是否涵盖肿瘤学主题,f1评分为0.84(0.77 - 0.91),精度为0.75,召回率为0.95。gpt - 40的f1评分为0.94 (95% CI: 0.90 - 0.99),预测出版物是否为RCT的精度为0.89,召回率为1.00。对于预测出版物是否涵盖肿瘤学主题,f1评分为0.91(0.85 - 0.97),精度为0.91,召回率为0.91。基于规则的系统能够正确地将测试集中的每个肿瘤RCT分配给肿瘤实体。结论:总之,根据是否为随机对照肿瘤学试验对出版物进行分类是可行的,并且可以使用更专业的工具(如基于规则的系统和潜在的专用机器学习模型)进行进一步处理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信